Florida International University

FIU Digital Commons
All Faculty

6-7-2017

ML290 is a biased allosteric agonist at the relaxin
receptor RXFP1
Martina Kocan
Monash University

Mohsin Sarwar
Monash University

Sheng Y. Ang
Monash University

Jingbo Xiao
National Institutes of Health

Juan J. Marugan
National Institutes of Health
See next page for additional authors

Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty
Recommended Citation
Kocan, Martina; Sarwar, Mohsin; Ang, Sheng Y.; Xiao, Jingbo; Marugan, Juan J.; Hossain, Mohammed A.; Wang, Chao; Hutchinson,
Dana S.; Samuel, Chrishan S.; Agoulnik, Alexander I.; Bathgate, Ross A. D.; and Summers, Roger J., "ML290 is a biased allosteric
agonist at the relaxin receptor RXFP1" (2017). All Faculty. 218.
https://digitalcommons.fiu.edu/all_faculty/218

This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized
administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors

Martina Kocan, Mohsin Sarwar, Sheng Y. Ang, Jingbo Xiao, Juan J. Marugan, Mohammed A. Hossain, Chao
Wang, Dana S. Hutchinson, Chrishan S. Samuel, Alexander I. Agoulnik, Ross A. D. Bathgate, and Roger J.
Summers

This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/all_faculty/218

www.nature.com/scientificreports

OPEN

Received: 1 February 2017
Accepted: 20 April 2017
Published: xx xx xxxx

ML290 is a biased allosteric agonist
at the relaxin receptor RXFP1
Martina Kocan1, Mohsin Sarwar1, Sheng Y. Ang1, Jingbo Xiao2, Juan J. Marugan2, Mohammed
A. Hossain 3, Chao Wang5, Dana S. Hutchinson 1, Chrishan S. Samuel5, Alexander I.
Agoulnik6, Ross A. D. Bathgate3,4 & Roger J. Summers 1
Activation of the relaxin receptor RXFP1 has been associated with improved survival in acute heart
failure. ML290 is a small molecule RXFP1 agonist with simple structure, long half-life and high stability.
Here we demonstrate that ML290 is a biased agonist in human cells expressing RXFP1 with long-term
beneficial actions on markers of fibrosis in human cardiac fibroblasts (HCFs). ML290 did not directly
compete with orthosteric relaxin binding and did not affect binding kinetics, but did increase binding
to RXFP1. In HEK-RXFP1 cells, ML290 stimulated cAMP accumulation and p38MAPK phosphorylation
but not cGMP accumulation or ERK1/2 phosphorylation although prior addition of ML290 increased
p-ERK1/2 responses to relaxin. In human primary vascular endothelial and smooth muscle cells that
endogenously express RXFP1, ML290 increased both cAMP and cGMP accumulation but not p-ERK1/2.
In HCFs, ML290 increased cGMP accumulation but did not affect p-ERK1/2 and given chronically
activated MMP-2 expression and inhibited TGF-β1-induced Smad2 and Smad3 phosphorylation. In
vascular cells, ML290 was 10x more potent for cGMP accumulation and p-p38MAPK than for cAMP
accumulation. ML290 caused strong coupling of RXFP1 to Gαs and GαoB but weak coupling to Gαi3.
ML290 exhibited signalling bias at RXFP1 possessing a signalling profile indicative of vasodilator and
anti-fibrotic properties.
In a recently completed phase III clinical trial (RELAX-AHF), serelaxin a recombinant form of the major stored
and circulating form of human relaxin 2 (H2) gene, reduced overall mortality and provided rapid relief of congestion as well as reducing organ damage1, 2. These effects likely reflect the cardioprotective actions of H2 relaxin that
include vasodilation, angiogenesis, anti-inflammatory and anti-fibrotic effects that have been shown in experimental models of cardiovascular disease3.
One likely target of H2 relaxin in humans is the vasculature because H2 relaxin has potent vasodilatory and
anti-fibrotic effects in human and rodent isolated blood vessels4, 5. At the cellular level, H2 relaxin binds to orthosteric binding sites in the leucine rich repeat (LRR) region and extracellular loop 2 (ECL2) leading to signal
transduction in human umbilical vascular cells where it acutely activates cAMP, cGMP and p-ERK1/2 signalling
and in the longer-term, increases the expression of nNOS, ETB and VEGFA6. In addition, H2 relaxin abrogates
fibrosis and prevents and/or reverses aberrant collagen deposition in numerous experimental models of disease,
regardless of etiology7–9. Despite the clinical promise of H2 relaxin, it has limitations as a therapeutic including cross-reactivity with other relaxin family peptide receptors9, no oral bioavailability and a short half-life of
<10 min10, requiring long term i.v. or s.c. infusions to produce a therapeutic effect. Therefore the development of
selective and orally bioavailable agonists of RXFP1 has potential significant benefits.
ML290 is the first small molecule agonist selective for RXFP111–13. It increases cAMP accumulation and VEGF
expression in cells that endogenously express human RXFP1 but not in cells that express RXFP2 or RXFP313. In
contrast to H2 relaxin, ML290 has a plasma half-life of 8.56 hr in mice without obvious toxicity13. ML290 activates
human, monkey and pig RXFP1, with no agonist actions at the mouse orthologue11, failing to compete directly
for orthosteric 125I-H2 relaxin binding to human RXFP1, suggesting an allosteric site of action13. Recent studies
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Figure 1. ML290 and binding of 125I-H2 relaxin to RXFP1 stably expressed in HEK293 cells. In (A) coincubation with ML290 (90 min), increased total binding of 125I-H2 relaxin to RXFP1 in a concentrationdependent manner (n = 6). In (B) ML290 (1 μM) had no significant effect on competition by H2 relaxin for 125IH2 relaxin binding (n = 8). In kinetic studies, ML290 (1 μM) had no significant effect on (C) dissociation (n = 3)
or (D) association rate (n = 6–7) of 125I-H2 relaxin from RXFP1. Data are mean ± SEM of ‘n’ experiments.
demonstrate that the binding site of ML290 is located in a binding pocket formed by the TM domains displaying
a strong hydrophobic interaction at the extracellular end of TM7 and forming a particularly important hydrogen
bond interaction with the ECL3 residues G659/T66011. To date, there is no detailed information available on the
signal transduction mechanisms utilised by ML290 in recombinant cell lines or in cells that endogenously express
RXFP1.
With this in mind, we have examined the binding and signalling profiles of ML290 in comparison with H2
relaxin. We measured cAMP accumulation, cGMP accumulation, p-ERK1/2 and p38MAPK phosphorylation
(p-p38MAPK) in HEK293T cells stably expressing RXFP1 (HEK-RXFP1) and in human primary vascular cells.
Moreover, we also investigated the potential anti-fibrotic properties of ML290 by evaluating its ability to promote markers such as matrix metalloproteinase (MMP)-2 and inhibit the pro-fibrotic actions of TGF-β1-induced
Smad-2 and Smad-3 phosphorylation in primary human cardiac fibroblasts, representing key fibrosis-producing
cells.

Results

Alteration of the binding characteristics of 125I-H2 relaxin by ML290 confirms an allosteric interaction with RXFP1. ML290 does not compete for 125I-H2 relaxin binding13 at the human RXFP1 and since

there is strong evidence from mutation studies that it binds to a topographically distinct site from that of H2
relaxin and displays species specificity14, it suggests an allosteric mode of action. Examination of the binding
profile in more detail in HEK-RXFP1 cells incubated with 125I-H2 relaxin (100pM), showed that ML290 concentration-dependently increased specific binding (pEC50: 8.8 ± 0.7) to RXFP1 from 102.7 ± 7.3% to 135.2 ± 6.5%
(p = 0.04) (Fig. 1A). In competition studies, ML290 (1 μM) had no significant effect on the affinity of H2 relaxin
(H2 relaxin pKi 9.5 ± 0.1 cf H2 relaxin + ML290 pKi 9.7 ± 0.1, Fig. 1B) confirming previous studies13. In kinetic
studies, ML290 (1 μM) had no significant effect on the dissociation rate of 125I-H2 relaxin in HEK-RXFP1 cells
(H2 relaxin Koff 0.05 ± 0.02 min−1 cf H2 relaxin + ML290 Koff 0.04 ± 0.01 min−1, Fig. 1C), nor on the association
rate (H2 relaxin Kon 2.1 × 108 M−1 min−1 cf H2 relaxin + ML290 Kon 2.8 × 108 M−1 min−1; Fig. 1D).

Comparison of the G-protein coupling profile produced H2 relaxin and ML290. There is evidence

using pertussis toxin resistant mutants of G proteins or specific G protein inhibitors, that H2 relaxin promotes
coupling of RXFP1 to Gαs, Gαi3 and Gαo/B in HEK-RXFP1 cells and in human primary vascular cells6, 15. To
determine the G-proteins involved in ML290-mediated signal transduction we have used real-time kinetic BRET
in HEK RXFP1 cells to directly examine ligand-induced interactions between RXFP1 and G-proteins.
HEK293T cells co-expressing RXFP1-Rluc8, Gγ2-Venus, Gβ1 and one of three Gα subunits (Gαs, GαoB, Gαi3,
or no Gα) were examined after treatment with H2 relaxin (100 nM) or ML290 (100 nM or 10 μM). H2 relaxin
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Figure 2. RXFP1 - G protein interactions and treatment with H2 relaxin or ML290. HEK-RXFP1-Rluc8 cells
were transiently co-transfected with Gγ2-Venus, Gβ1 and one of Gα subunits (Gαs, GαoB, Gαi3). Interactions
between RXFP1 and G proteins were detected prior to and after treatment with H2 relaxin (0.1 μM) or ML290
(0.1 μM or 10 μM) using real-time BRET assays. Both ML290 and H2 relaxin induced interactions between
RXFP1-Rluc8 and Gαs, GαoB, and to a lesser extent Gαi3 (A–C). Shifts in BRET ratio between RXFP1 and Gαs
were quantitatively and qualitatively similar with ML290 and H2 relaxin. However the ML290 RXFP1- GαoB
ligand-induced BRET ratio moved in the opposite direction to that to H2 relaxin (B) suggesting that each ligand
induces a different receptor conformation. Interactions between RXFP1 and Gαi3 with H2 relaxin and ML290
were weak but qualitatively similar. There were no interactions between RXFP1-Rluc8 and Gγ2-Venus in the
absence of Gα subunits (D). Ligand-induced BRET ratios were calculated by subtracting the BRET ratio for
the vehicle-treated sample from that obtained from each ligand-treated sample as described in Materials and
Methods. Data are mean ± SEM of 4 independent experiments.

and ML290 promoted interactions between RXFP1 and Gαs, Gαo/B and to a lesser extent Gαi3 (Fig. 2). The profile
of ML290 and H2 relaxin-induced BRET between RXFP1 and Gαs was almost identical (Fig. 2A) whereas the
profile for ML290-induced BRET for RXFP1-GαoB interactions clearly differed from that observed for H2 relaxin
(Fig. 2B). Both ligands produced a small but similar response with Gαi3 (Fig. 2C). These interactions were specific for RXFP1 and Gαs, GαoB and Gαi3 because control studies in HEK293T cells co-expressing RXFP1-Rluc8,
Gγ2-Venus, Gβ1 but no Gα subunits, showed no H2 relaxin or ML290-induced BRET (Fig. 2D). All G-protein
constructs used in this study have been validated and shown to be functional16.

MAPK and cAMP activation by H2 relaxin and ML290 in HEK-RXFP1 cells. Time course studies
showed that ERK1/2 phosphorylation (p-ERK1/2) was observed with H2 relaxin (100 nM) but not with direct
addition of ML290 (100 nM or 10 μM) (Figure S1A). Both H2 relaxin (100 nM) and ML290 (100 nM or 10 μM)
increased p38MAPK phosphorylation (Figure S1B) but had no effect on JNK1/2 phosphorylation (p-JNK1/2/3)
(Figure S1C). These responses were mediated by RXFP1 as all ligands failed to cause p-ERK1/2 and p-p38MAPK
responses in HEK293T cells lacking RXFP1 (data not shown).
Concentration-response relationships for p-ERK1/2 at 5 min showed that H2 relaxin had a high potency
(pEC50: 9.5 ± 0.3; Table 1) and efficacy (Emax: 31.8 ± 1.7% of the response to 10% FBS) whereas ML290 failed to
produce a response (Fig. 3A). However, both H2 relaxin (pEC50: 8.9 ± 0.3) and ML290 (pEC50: 9.3 ± 0.6) produced
p-p38MAPK responses at 15 min with similar potency (NS, Table 1) although H2 relaxin had higher efficacy (Emax
H2 relaxin: 29.8 ± 1.7% cf Emax ML290: 16.9 ± 2.2%; P < 0.005) (Fig. 3B). ML290 was a weaker agonist for cAMP
accumulation in HEK-RXFP1 cells than H2 relaxin. Incubation with ML290 or H2 relaxin for 30 min increased
cAMP accumulation in HEK-RXFP1 cells to a maximum of 113.3 ± 1.8% and 129.0 ± 5.8% of the response to forskolin (50 μM), respectively (Fig. 3C). H2 relaxin had significantly higher potency (pEC50: 10.3 ± 0.1) than ML290
(pEC50: 6.4 ± 0.1; P < 0.0001; Table 1) despite having similar efficacy (Fig. 3C). Pretreatment (10 min) with ML290
(10 μM) significantly increased the maximum p-ERK1/2 response to relaxin without altering potency (Fig. 3D).
In human primary cells, ML290 causes cAMP and cGMP accumulation but not ERK1/2 phosphorylation in smooth muscle and endothelial cells and cGMP accumulation but not ERK1/2 phosphorylation in cardiac fibroblasts. H2 relaxin is known to increase cAMP accumulation in HUVEC,

HUASMC and HUVSMC6, 17 (Table 1). ML290 (30 min) also concentration-dependently increased cAMP accumulation (Fig. 4A) up to 17.9 ± 3.3% of the forskolin response (50 μM, 30 min) in HCAECs (pEC50: 6.1 ± 0.3),
Scientific Reports | 7: 2968 | DOI:10.1038/s41598-017-02916-5
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p-ERK1/2 (% 10% FBS)

p-p38MAPK (% sorbitol)

H2 relaxin

ML290

H2 relaxin

ML290

HEK-RXFP1

9.5 ± 0.3 (4) (31.8 ± 1.7)

NE (8)

8.9 ± 0.3 (4) (29.8 ± 1.7)

9.3 ± 0.6 (6) (16.9 ± 2.2)

HCAEC

ND

NE (3)

ND

NE (3)

HUVEC

9.2 ± 0.3# (5) (11.2 ± 2.7)

NE (3)

ND

NE (3)

HUASMC

9.1 ± 0.4# (6) (27.7 ± 8.1)

NE (3)

ND

8.6 ± 0.6 (3) (4.4 ± 1.6)

HUVSMC

9.2 ± 0.4# (6) (15.2 ± 4.4)

NE (3)

ND

8.5 ± 1.0 (3) (2.7 ± 0.9)

HCF

9.1 ± 0.3# (5) (54.7 ± 15.9)

NE (3)

ND

ND

cGMP (% DEA 1 μM)

cAMP (% forskolin 50 μM)

HEK-RXFP1

NE (3)

NE (3)

HCAEC

9.2 ± 0.5 (3) (39.6 ± 14.8)

7.2 ± 0.4 (7) (40.6 ± 5.6)

8.9 ± 0.5 (3) (13.0 ± 5.2)

6.1 ± 0.3 (7) (17.9 ± 3.3)

HUVEC

8.9 ± 0.4# (7) (65.4 ± 19.8)

7.3 ± 0.5 (7) (23.5 ± 4.4)

9.1 ± 0.4# (9) (6.0 ± 2.7)

6.2 ± 0.7 (7) (11.7 ± 3.9)

HUASMC

9.1 ± 0.3# (6) (55.7 ± 12.4)

7.2 ± 0.5 (7) (21.0 ± 4.1)

9.0 ± 0.3# (7) (4.5 ± 1.6)

6.2 ± 0.5 (5) (11.9 ± 3.9)

HUVSMC

9.2 ± 0.4 (6) (31.4 ± 10.9)

7.2 ± 0.6 (4) (11.0 ± 3.4)

9.6 ±0.4# (10) (5.1 ± 1.8)

6.1 ± 0.5 (4) (10.8 ± 3.0)

HCF

9.6 ± 0.7 (5) (62.3 ± 7.6)

7.5± 0.3 (5) (45.3 ± 4.1)

NE (3)

ND

#

10.3 ± 0.1 (5) (129.0 ± 5.8) 6.4 ± 0.1 (6) (113.3 ± 1.8)

Table 1. The potency of ML290 and relaxin in HEK-RXFP1 and human primary vascular cells for p-ERK1/2,
pp38MAPK, cGMP and cAMP accumulation. Note: #Indicates data taken from our previous publication
conducted in the same cells6. Efficacy (below in brackets) expressed as a % of control responses for each
pathway. N numbers in brackets. NE – no effect; ND – not determined.

Figure 3. Activation of ERK1/2, p38MAPK and generation of cAMP by H2 relaxin and ML290. In HEKRXFP1 cells, H2 relaxin activated p-ERK1/2 (A) 5 min), p-p38MAPK (B) 15 min) and cAMP accumulation (C)
30 min) in a concentration-dependent manner. ML290 did not directly activate p-ERK1/2 (A), but did activate
p38MAPK (B) with lower efficacy and cAMP accumulation with similar efficacy but significantly lower potency
than H2 relaxin (C). 10 min pretreatment with ML290 enhanced p-ERK1/2 activation produced by relaxin (D)
4 min). Data are mean ± SEM for 4–8 independent experiments.
11.7 ± 3.9% in HUVECs (pEC50: 6.2 ± 0.7), 10.8 ± 3.0% in HUVSMCs (pEC50: 6.1 ± 0.5) and 11.9 ± 3.9% in
HUASMCs (pEC50: 6.2 ± 0.5). ML290 was 3 orders of magnitude less potent than H2 relaxin (Table 1). ML290
did not cause cAMP accumulation in HUAEC (Fig. 4A), cells known not to express cell surface RXFP16.
Although the concentration-response curve (CRC) to H2 relaxin in HEK-RXFP1 cells was bell-shaped
(Fig. 3C) as in human primary vascular cells6, that to ML290 was right-shifted and incomplete due to limitations
on the concentration that could be added, and therefore no conclusion can be reached regarding the shape of the
ML290 concentration-response curve.
H2 relaxin also activates cGMP signalling in a variety of cells18, 19 including human primary vascular cells6.
ML290 (30 min) also concentration-dependently increased cGMP accumulation (Fig. 4B) to 40.6 ± 5.6% of
the DEA response (10 μM, 5 min) in HCAECs (pEC50: 7.2 ± 0.4), 23.5 ± 4.4% in HUVECs (pEC50: 7.3 ± 0.5),
11.0 ± 3.4% in HUVSMCs (pEC50: 7.2 ± 0.6) and 21.0 ± 4.1% in HUASMCs (pEC50: 7.2 ± 0.5). ML290 had no
effect on cGMP accumulation in HUAEC (Fig. 4B), the cells that do not express cell surface RXFP16. It was of
interest to note that the potency of ML290 in the cGMP assay was greater than an order of magnitude higher
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Figure 4. Signal transduction pathways activated by ML290 in human primary vascular cells and in human
cardiac fibroblasts (HCF). In (A) ML290 (30 min) concentration-dependently increased cAMP accumulation in
HCAECs ( , n = 7), HUVECs ( , n = 7), HUASMCs ( , n = 5), HUVSMCs ( , n = 4) but not in HUAECs that
do not express cell surface RXFP1 ( , n = 4); in (B) ML290 (30 min) also increased cGMP accumulation in
HCAECs (n = 7), HUVECs (n = 7), HUASMCs (n = 7), HUVSMCs (n = 4) but not in HUAECs (n = 4); In (C)
ML290 increased p-p38MAPK (15 min) but only in HUASMC and HUVSMCs (n = 3); In (D) ML290 did not
cause ERK1/2 phosphorylation in HCAECs (n = 3), HUVECs (n = 3), HUASMCs (n = 3), HUVSMCs (n = 3) or
HUAECs (n = 3). In HCFs, H2 relaxin activated cGMP accumulation in a concentration-dependent manner
((E) n = 5) (40 min) and p-ERK1/2 ((F) n = 3) (5 min). ML290 did not activate p-ERK1/2 (F; n = 3) but did
induce cGMP accumulation (E; n = 5) in a concentration-dependent manner albeit with lower potency than H2
relaxin. Data shown are mean ± SEM of ‘n’ independent experiments.

than that observed in the cAMP assay (Table 1). In order to determine whether the vehicle for ML290 affected
the potency of ligands acting at RXFP1, HCAECs, HUVECs, HUASMCs and HUVSMCs were treated with H2
relaxin and DMSO (1%) which had no significant effect on potency or efficacy for cAMP or cGMP accumulation
(Figure S2).
ML290 concentration-dependently increased p-p38MAPK (Fig. 4C) in HUASMC to 4.4 ± 1.6% of the sorbitol
response (pEC50: 8.6 ± 0.6) and to 2.7 ± 0.9% of the sorbitol response in HUVSMC (pEC50: 8.5 ± 1.0) (Table 1)
but did not activate p-p38MAPK in HUVEC and HCAEC despite ML290 causing a cAMP (Fig. 4A) and cGMP
(Fig. 4B) response in these cells.
H2 relaxin is known to stimulate a cGMP responses in HCFs6. Here, we have shown that ML290 also produces
concentration-dependent cGMP accumulation in HCFs (Fig. 4E). ML290 induced cGMP signalling with somewhat lower efficacy and potency (Emax: 45.3 ± 4.1% of the response to 10 μM DEA and pEC50: 7.5 ± 0.3) compared
to H2 relaxin (Emax: 62.3 ± 7.6% of the response to 10 μM DEA and pEC50: 9.6 ± 0.7).
H2 relaxin increases p-ERK1/2 in human primary vascular cells and in HCFs (confirmed here, Fig. 4F)6.
However, in addition to HEK-RXFP1 cells, ML290 had no effect when added directly on p-ERK1/2 in HCAECs,
HUVECs, HUASMCs and HUVSMCs (Fig. 4D) or in HCF whereas the positive control (FBS: 10%, 5 min) caused
a 4-fold increase in human primary vascular cells (Fig. 4D) and a 9-fold increase in p-ERK1/2 in HCFs Fig. 4F).

Effect of signalling pathway inhibitors on cAMP and cGMP signalling activated by ML290 in
human primary vascular cells. We next examined the effects of specific inhibitors of G proteins and sig-

nalling pathways activated by ML290 associated with cAMP and cGMP accumulation in human vascular cells.
We utilized the Gαs inhibitor (NF449), the Gαi/o inhibitor (NF023), the βγ inhibitors (mSIRK and gallein) and
the PI3K inhibitor (Wortmannin). In endothelial cells, NF449 (10 μM, 30 min) reduced ML290-mediated cAMP
accumulation (% response to 50 μM forskolin) in HCAECs (Figs 5A and S3A) from 22.5 ± 5.5% to 0.8 ± 3.9%
Scientific Reports | 7: 2968 | DOI:10.1038/s41598-017-02916-5
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Figure 5. The role of G proteins, βγ subunits and PI3-kinase in ML290-mediated cAMP and cGMP
accumulation in human primary vascular cells. ML290 (10 μM, 30 min) increased cAMP accumulation in
HCAECs ((A) n = 5), HUVECs ((B) n = 8), HUASMCs ((C) n = 8) and HUVSMCs ((D) n = 4). Treatment
with the Gαs inhibitor NF449 (10 μM, 30 min) of HCAECs ((A) n = 3) and HUVECs ((B) n = 4) abolished
ML290-mediated cAMP accumulation (30 min) whereas in HUASMCs ((C) n = 4) and HUVSMCs ((D) n = 4)
it reduced the maximum cAMP response. The Gαi/GαOB inhibitor NF023 (10 μM, 30 min) in HCAECs ((A)
n = 4) and HUVECs ((B) n = 4), HUASMCs ((C) n = 4) and HUVSMCs ((D) n = 4) had no effect on ML290mediated cAMP accumulation. Pre-treatment of HCAECs ((A) n = 3) and HUVECs ((B) n = 3) with the
Gβγ inhibitors mSIRK (5 μM, 30 min) and gallein (50 μM, 45 min) and the PI3-kinase inhibitor Wortmannin
(100 nM, 30 min) had no effect on ML290-mediated cAMP accumulation whereas pre-treatment of HUASMCs
((C) n = 3) or HUVSMCs ((D) n = 3) with both Gβγ inhibitors and the PI3-kinase inhibitor reduced the
maximum cAMP response to ML290. ML290 (10 μM, 30 min) also increased cGMP accumulation in HCAECs
((E) n = 3), HUVECs ((F) n = 4), HUASMCs ((G) n = 3) and HUVSMCs ((H) n = 3). NF449 (10 μM, 30 min)
pre-treatment of HCAECs ((E) n = 4); HUVECs ((F) n = 3), HUASMCs ((G) n = 6) and HUVSMCs ((H)
n = 4) reduced the maximum ML290-mediated cGMP response. Pretreatment with NF023 (10 μM, 30 min)
of HCAECs ((E) n = 3), HUVECs ((F) n = 3), HUASMCs ((G) n = 4) and HUVSMCs ((H) n = 4) had no
effect on ML290-mediated cGMP accumulation. Pretreatment with the Gβγ inhibitors mSIRK (5 μM, 30 min)
and gallein (50 μM, 45 min) and the PI3-kinase inhibitor Wortmannin (100 nM, 30 min) had no effect on
cGMP accumulation in HCAECs ((E) n = 3) and HUVECs ((F) n = 3) whereas in HUASMCs ((G) n = 5) and
HUVSMCs ((H) n = 4), it reduced the maximum response. Pre-treatment of HUASMCs ((C,G) n = 4–11)
and HUVSMCs ((D,H) n = 4–5) with mSIRK control peptide L9A (5 μM, 30 min) had no significant effect
on ML290-mediated cAMP or cGMP accumulation. Statistical significance was assessed using a one-way
ANOVA with a Dunnet’s post-hoc test compared to ML290 alone: **p < 0.01 and *p < 0.05. Data shown are
mean ± SEM of ‘n’ independent experiments.
(p < 0.05) and in HUVECs (Figs 5B and S3B) from 16.4 ± 2.5% to 0.8 ± 5.7% (p < 0.05). In these endothelial
cells, ML290-mediated cAMP accumulation was unaffected by NF023 (10 μM, 30 min), mSIRK (5 μM, 30 min),
gallein (50 μM, Fig. 5A,B) or Wortmannin (100 nM, 30 min, Fig. 5A,B), suggesting that ML290-mediated cAMP
signalling in these cells was predominantly regulated by Gαs.
In contrast, in smooth muscle cells, NF449 (10 μM, 30 min) only partially but significantly inhibited
ML290-mediated cAMP accumulation in HUASMCs (Figs 5C and S3C) from 18.8 ± 4.3% to 6.0 ± 7.3%
(p < 0.05) and in HUVSMCs (Figs 5D and S3D) from 18.8 ± 8.0% to 4.7 ± 2.5% (p < 0.05). Unlike endothelial
cells, in smooth muscle cells, mSIRK (5 μM, 30 min, Figs 5C,D and S3C,D) reduced ML290-mediated cAMP
accumulation in HUASMCs from 18.8 ± 4.3% to 9.1 ± 3.3% (p < 0.05) and HUVSMCs from 18.8 ± 8.0% to
3.9 ± 2.5% (p < 0.05). Another βγ inhibitor, gallein (50 μM, Fig. 5C,D), produced similar results to mSIRK
reducing ML290-mediated cAMP accumulation in HUASMCs from 16.7 ± 3.4% to 5.2 ± 1.4% (p < 0.05) and
in HUVSMCs from 12.6 ± 2.4% to 3.2 ± 3.4% (p < 0.05). Since PI3K is downstream of βγ subunits15, we used
Wortmannin (100 nM, 30 min, Fig. 5C,D) to determine its role in ML290 signalling and showed inhibition of
ML290-mediated cAMP accumulation in HUASMCs from 16.7 ± 3.4% to 7.2 ± 2.2% (p < 0.05) and HUVSMCs
from 12.6 ± 2.4% to 6.4 ± 2.2% (p < 0.05). In these cells, like endothelial cells, pre-treatment with the Gi/o inhibitor NF023 (10 μM, 30 min, Figs 5C,D and S3C,D) had no effect on ML290-mediated cAMP accumulation in
HUASMC and HUVSMC.
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Figure 6. ML290 effects on MMP-2 expression and TGF-β1-induced Smad2 and Smad3 phosphorylation in
HCFs. ML290 (1 μM) promoted MMP-2 activity to an equivalent extent to H2 relaxin (0.1 μM) over 72 hours.
In (A upper) a representative cropped zymograph (see Figure S4) of duplicate samples from two separate
experiments; in (A lower) mean ± SE OD MMP-2, expressed as the ratio of that of in the untreated control
group. **p < 0.01 versus untreated control group. In HCFs treated for 72 hours, ML290 (1 μM) inhibited TGFβ1-induced increases in p-Smad2 (B, n = 4) and increases in p-Smad3 (C, n = 4) to a level similar to that with
H2 relaxin (0.1 μM). TGF-β1 (2 ng/ml) increased p-Smad2 (B) and p-Smad3 (C) compared to vehicle treated
samples. Neither H2 relaxin (0.1 μM) nor ML290 (1 μM) had a significant effect on p-Smad2 or p-Smad3 in cells
not treated with TGF-β1 (B,C). Data are mean ± SEM of 4 independent experiments performed in duplicate,
**p < 0.01 and *p < 0.05.

H2 relaxin-mediated cGMP accumulation in HUVECs, HUVSMCs and HUASMCs is known to be mediated
by Gαs, Gαi/o and PI3K6. Using pathway-specific inhibitors in endothelial cells, we found that NF449 significantly
reduced the maximum response to ML290 in HCAECs (Figs 5E and S3E) from 41.0 ± 4.5% to 11.9 ± 5.3% and
HUVECs (Figs 5F and S3F) from 39.5 ± 4.8% to 22.3 ± 3.0% of the response to DEA. However, ML290-mediated
cGMP accumulation was not significantly affected by NF023 (10 μM, 30 min; Figs 5E,F and S3E,F), mSIRK (5 μM,
30 min; Figs 5E,F and S3E,F), gallein (50 μM, Fig. 5E,F) or Wortmannin (100 nM, 30 min, Fig. 5E,F) suggesting
that ML290-mediated cGMP signalling, like cAMP signalling, in human primary endothelial cells was predominantly regulated by Gαs.
In smooth muscle cells, NF449 (10 μM, 30 min) also reduced ML290-mediated cGMP accumulation in
HUASMCs (Figs 5G and S3G) from 41.9 ± 4.8% to 24.3 ± 5.7% (p < 0.05) and in HUVSMCs (Figs 5H and S3H)
from 31.4 ± 4.8% to 18.8 ± 3.7% (p < 0.05). In contrast to cGMP responses in endothelial cells, mSIRK (5 μM,
30 min, Figs 5G,H and S3G,H) reduced ML290-mediated cGMP accumulation in HUASMCs from 41.9 ± 4.8%
to 20.1 ± 3.9% (p < 0.05) and in HUVSMCs from 31.4 ± 4.8% to 13.4 ± 3.5% (p < 0.01). Gallein (50 μM,
Fig. 5G,H) had similar effects to mSIRK and inhibited ML290-mediated cGMP accumulation in HUASMCs
from 32.1 ± 4.2% to 15.6 ± 2.6% (p < 0.05) and HUVSMCs from 30.4 ± 3.2% to 14.3 ± 3.8% (p < 0.05).
Wortmannin (100 nM, 30 min, Fig. 5G,H) also inhibited ML290-mediated cGMP accumulation in HUASMCs
from 32.1 ± 4.2% to 21.8 ± 3.4% (p < 0.05) and HUVSMCs from 30.4 ± 3.2% to 14.3 ± 3.3% (p < 0.05). However,
NF023 (10 μM, 30 min, Figs 5C,D and S3C,D) pre-treatment had no effect on ML290-mediated cGMP accumulation in HUASMC and HUVSMC suggesting that as for cAMP accumulation Gαi/o was not involved.

Chronic ML290 promotes MMP-2 expression and inhibits TGF-β1-induced Smad2 and Smad3
phosphorylation in HCFs. To evaluate potential anti-fibrotic effects of ML290 and compare it to the known

effects of H2 relaxin we examined the effects of both mediators on MMP-2 expression and Smad2 and Smad3
phosphorylation (targets of the anti-fibrotic actions of H2 relaxin; refs 20 and 21) in fibrosis-producing HCFs.
H2 relaxin positively regulates one the main collagen-degrading MMPs, MMP-2, in HCFs6. Here, we have
investigated the effects of ML290 on MMP-2 in the same cells under the same experimental conditions (Fig. 6A).
ML290 (1 μM) increased MMP-2 expression in HCFs by ·40%, as did recombinant H2 relaxin (0.1 μM) when
given over 72 hours in culture (both p < 0.01 versus untreated controls).
H2 relaxin, acting on RXFP1, inhibits aberrant myofibroblast differentiation and collagen deposition by disrupting the TGF-β1/Smad221 and TGF-β1/Smad320 axis. In TGF-β1-stimulated HCFs, both H2 relaxin (0.1 μM)
and ML290 (1 μM) significantly decreased p-Smad2 and p-Smad3 levels (Fig. 6B,C). Cells treated with TGF-β1
(2 ng/ml) showed a 2.21 ± 0.17-fold increase in p-Smad2 and 1.41 ± 0.07-fold increase in p-Smad3 compared to
vehicle-treated samples. Both H2 relaxin (p-Smad2: 1.74 ± 0.13-fold/basal, p < 0.05; p-Smad3: 1.11 ± 0.04-fold/
basal, p < 0.01) and ML290 (p-Smad2: 1.58 ± 0.34-fold/basal, p < 0.05; p-Smad3: 1.15 ± 0.05-fold/basal, p < 0.01)
significantly inhibited the TGF-β1-induced increase in p-Smad2 and p-Smad3 in HCFs. In contrast, in HCFs not
treated with TGF-β1, neither H2 relaxin (0.1 μM) nor ML290 (1 μM) significantly affected p-Smad2 or p-Smad3
levels (Fig. 6B,C).
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Figure 7. Chemical structure of ML29013. 2-Isopropoxy-N-(2-(3-(tri fluoromethyl sulfonyl) phenyl carbamoyl)
phenyl) benzamide.

Discussion

ML290 was discovered by high throughput screening of >350,000 small molecules followed by lead optimisation
(Fig. 7)13. ML290 was reported to have selectivity for RXFP1, high nanomolar potency in cAMP assays and did
not compete with H2 relaxin binding. Interaction with an allosteric site was considered likely because of the
complex mode of interaction of H2 relaxin with the orthosteric binding sites on RXFP1. This involves the binding
of H2 relaxin with high affinity to the leucine rich repeat (LRR)22, 23 and to the LRR-LDLa linker region24 in the
ectodomain of RXFP1 such that binding to the latter region stabilizes and extends a helical conformation within
the linker that acts as the critical switch for LDLa-mediated receptor activation24. Thus for signalling involving
the H2 relaxin peptides, the LDLa module is essential and behaves as a tethered ligand to activate RXFP1 via
interactions at an allosteric activation site on the TM domain24, 25. Receptors that lack the LDLa module or contain
mutations that disrupt its structure26, 27 or the predicted functional amino acids that drive activation27, 28 bind H2
relaxin with high affinity but do not signal. However, and in contrast to H2 relaxin, ML290 still activates cAMP
production with LDLa mutant receptors13, 24 or with an LDLa-less receptor (data not shown) suggesting a different mode of action.
The agonist actions of ML290 are also species-specific being confined to the human, monkey and pig RXFP1
with antagonist actions at the mouse11, 14. These actions are interesting as it suggests that ML290 interacts with a
binding site that overlaps with that thought to be activated by the LDLa module. Mutation and modelling studies
demonstrate that the site is located within a binding pocket formed by the TM domains with ML290 mainly
interacting with a hydrophobic patch W664/I667/F668 located at the extracellular end of TM7 and with G659/
T660 in ECL311, 13. The interaction with ECL3 is particularly important for the specificity of action of ML290 at
RXFP1. Differences in G659/T660 in RXFP2 or across species RXFP1 determine whether ML290 produces the
conformational changes required for an agonist action11, 13. These properties together with the initial evidence
that ML290 does not directly compete for 125I-H2 relaxin binding at the orthosteric binding sites on human
RXFP1 suggests an allosteric mode of action. The current approach provided additional supporting evidence
for this view from detailed binding studies. We found that ML290 does not alter the affinity of H2 for RXFP1
in competition studies (Fig. 1B), producing instead a concentration-dependent small potentiation in binding of
125
I-H2 relaxin toward RXFP1 (Fig. 1A) possibly mediated by conformational changes induced by binding to the
allosteric site. Examination of the kinetics of binding showed that ML290 did not affect either the rate of association or dissociation of 125I-H2 relaxin at RXFP1 thus presenting ML290 as an agonist acting at a topographically
distinct allosteric activation site that has minimal effects on the binding of H2 relaxin. The data is consistent with
the LDLa module being a tethered ligand that interacts with the TM domain to initiate activation. It is possible
that the binding site of ML290 is in close apposition to the LDLa interaction site.
Previous studies have used PTX-resistant variants of G proteins to establish that RXFP1 couples to Gαs to
increase cAMP, an effect that is negatively modulated by coupling to GαOB15. There is also coupling to Gαi315, 29, 30
that results in activation of PI-3-kinase and translocation of PKCζ to produce delayed stimulation of adenylyl
cyclase V to cause a late surge of cAMP. In the present studies we have examined coupling to G proteins using
BRET to directly compare the patterns produced by H2 relaxin and ML290. Both H2 relaxin and ML290 produced changes in the BRET ratio between RXFP1 and Gαs or Gαi3 that were quantitatively and qualitatively
similar (Fig. 2A,C). However the pattern of BRET ratios between RXFP1 and GαOB produced by H2 relaxin and
ML290 were clearly different (Fig. 2B) suggesting that these ligands cause different conformational changes in
the receptor.
The pattern of G protein coupling was also examined in human primary vascular cells using the specific
G-protein inhibitors, NF449 (Gαs)31, NF023 (Gαi/o)32 and mSIRK (Gβγ)33 for cAMP and cGMP signalling. The
results were in broad agreement with those using BRET in HEK cells and confirmed that Gαs was the major
G-protein involved although again there were cell type differences. Thus, in endothelial cells, cAMP and cGMP
responses were blocked by NF449 but not affected by NF023 or mSIRK whereas in smooth muscle cells both
NF449 and mSIRK reduced responses. Another Gβγ inhibitor gallein34 produced the same effects as mSIRK
and the control peptide L9A had no effect. The lack of effect of NF023 on cAMP or cGMP accumulation may
be related to blockade of both inhibitory GαOB and stimulatory Gαi3 that would tend to cancel out any change.
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Figure 8. Comparison of signalling pathways activated by ML290 and H2 relaxin through RXFP1 expressed
in human primary vascular cells and myofibroblasts. In human primary myofibroblasts both H2 relaxin and
ML290 have a profile corresponding to anti-fibrotic activity yet ML290 achieves this without activating ERK.
In human primary vascular cells H2 relaxin activates cAMP, cGMP and pERK with similar potency whereas
ML290 is biased towards cGMP signalling compared with cAMP and does not activate pERK.
It is likely that the effects downstream of Gβγ involve PI-3-kinase since the PI-3-kinase inhibitor Wortmannin
produced a similar pattern to gallein.
Comparison of the signalling pathways that were activated by H2 relaxin and ML290 in HEK-RXFP1 cells
showed that while both H2 relaxin and ML290 caused increases in cAMP and p-p38MAPK only H2 relaxin
activated p-ERK1/2 (Fig. 8), and neither ligand activated p-JNK1/2/3. Previous studies have shown that the PKA
inhibitor H89 inhibited p38MAPK phosphorylation in response to relaxin in HEK-RXFP1 cells35. Since H2
relaxin does not promote internalisation, it is unlikely that the lack of a pERK1/2 response to direct application
of ML290 results from a lack of β-arrestin recruitment and internalisation. Our findings show that in addition
to acting allosterically, ML290 displayed signalling bias showing similar potency to H2 relaxin for activation of
p-p38MAPK, lower potency than H2 relaxin for cAMP generation and unlike H2 relaxin being ineffective in
activating pERK1/2. The enhancement of the pERK response to relaxin by ML290 was interesting and indicated
that ML290 does not directly occupy the activation site utilised by the LDLa module at the human RXFP1. Rather
it resembles the small enhancement of 125I H2 relaxin binding seen with ML290 suggesting that this could be
responsible and both effects could result from a change in the conformation that RXFP1 can adopt when the
allosteric site is occupied. Further studies will be required to clarify this point.
Since there is particular interest in the cardiovascular effects of H2 relaxin in humans, we examined signalling pathways in human primary vascular cells. Previous studies show that H2 relaxin activates cAMP, cGMP
and ERK1/2 signalling (Fig. 8) in human endothelial and smooth muscle cells6 and that the cGMP response
was greatly enhanced in co-cultures of endothelial and smooth muscle cells17. Like H2 relaxin, ML290 produced cAMP and cGMP responses in HCAEC, HUVEC, HUASMC, HUVSMC (Fig. 8) but not in HUAEC that
have been shown to lack cell surface expression of RXFP16. A particularly interesting observation was that the
concentration-response relationship for cGMP responses produced by ML290 was shifted to the left by more than
an order of magnitude compared to that for cAMP (Fig. 4). In addition, ML290 produced p-p38MAPK responses
only in smooth muscle and not in endothelial cells and in none of the cell types was there a pERK1/2 response
recorded to direct addition of ML290.
Comparison of the patterns of signalling to ML290 in recombinant and human primary cell systems showed
that cAMP signalling was similar as was the lack of a p-ERK1/2 response (Fig. 8). However, in HEK-RXFP1 cells,
both ML290 and H2 relaxin failed to cause cGMP accumulation (data not shown) whereas it was a dominant
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response in human primary vascular cells, suggesting that the cellular background has a significant role to play
in determining the signal transduction mechanisms observed with both H2 relaxin and ML290. p-p38MAPK
responses were only observed in HEK cells and human smooth muscle cells. Thus, not only is there signalling bias
displayed by ML290 there is also tissue bias that influences the signalling pathways observed.
The effect of ML290 on cAMP and cGMP may be clinically relevant since ML290 shows bias towards cGMP
signalling in human primary vascular cells that suggests that ML290 may be a vasodilator. cGMP regulates vascular tone by regulating cytosolic Ca2+ levels in smooth muscle cells, Ca2+ sensitivity of myofilaments and smooth
muscle cell proliferation and differentiation36–38. ML290 also stimulated cGMP signalling in endothelial cells
(Fig. 4B) that contribute to angiogenesis38 a role supported by evidence that ML290 increases VEGF expression13.
ML290 also activated cAMP signalling in human primary vascular cells, albeit with a lower potency than cGMP.
cAMP has conflicting roles, being pro-arrhythmic and producing increases in heart rate and intracellular Ca2+
levels, factors that may be detrimental to myocardial infarction and heart failur39, 40. However there may also be
beneficial effects since transgenic mice with increased cardiac ACVI expression that underwent acute myocardial
infarction showed an increase in cAMP levels but reduced left ventricular remodelling and mortality41. Therefore,
the role of ML290 in cardiac (patho)physiology will be important to determine.
Another important finding was that in contrast to H2 relaxin6, direct addition of ML290 failed to cause
ERK1/2 activation (Table 1 and Figs 3, 4 and 8). ERK1/2 signalling plays an important role in cardiac hypertrophy42 a compensatory mechanism accompanying heart failure that is beneficial in the early stages but later leads
to failure42. Since ERK and other MAPKs such as p38MAPK and JNK also play important roles in cardiomyocyte
survival42 and can promote TGF-β1 signal transduction and cardiac fibrosis43, the pathophysiological relevance
of the lack of ERK1/2 activation (Figs 3 and 4) and cell-dependent p38MAPK phosphorylation (Figs 3 and 4) by
ML290, and the interaction of relaxin and ML290 on pERK1/2 signalling will need further investigation.
Comparison of the bias profile of ML290 with the recently described functionally selective single chain relaxin
derivative B7-3344 reveals some important differences. Unlike ML290, B7-33 competes with relaxin binding at
the orthosteric site and promotes cAMP accumulation following stimulation of rat and mouse RXFP1 as well
as human RXFP1 albeit with 3–5 orders of magnitude lower potency than H2 relaxin44. Like ML290, B7-33 has
little if any activity at RXFP244. In contrast to ML290, that displayed no ERK1/2 activation in any system tested,
B7-33 is a strong activator of ERK1/2 in rat renal myofibroblasts with a potency and efficacy comparable with
H2 relaxin44. B7-33 and H2 relaxin increase MMP2 activity by similar mechanisms44 whereas the direct effect of
ML290 is not associated with ERK1/2 activation.
The anti-fibrotic actions of H2 relaxin, including its ability to inhibit the TGF-β1/p-Smad2 axis and
TGF-β1-induced myofibroblast differentiation and collagen deposition, while promoting collagen-degrading
MMPs, have been shown to be mediated through RXFP1-ERK1/2 signalling in HCFs6, human dermal fibroblasts45
and rat renal myofibroblasts46–48. In these studies, it was suggested that H2 relaxin stimulated cGMP accumulation
down-stream of its ability to activate p-ERK1/2 through a RXFP1-p-ERK1/2-nNOS-NO-sGC-cGMP-dependent
pathway because: (i) H2 relaxin stimulated pERK1/2 and cGMP within minutes of administration to (myo)fibroblast cultures, but it required 48–72 hours to stimulate nNOS expression in HCFs and rat renal myofibroblasts,
and these effects were abrogated by the MEK inhibitor, PD9805946; (ii) the inhibition of the TGF-β1/p-Smad2
axis and α-SMA expression (used as a marker of myofibroblast differentiation) by H2 relaxin over 72 hours was
blocked by the nNOS inhibitor, N-propyl-L-arginine, or the sGC inhibitor ODQ; and (iii) sGC is the only known
receptor for NO that stimulates cGMP accumulation, leading to the proposal that cGMP is acting downstream
of NO-sGC. The finding that ML290 rapidly stimulated cGMP accumulation without ERK1/2 activation, and
independently that H2 relaxin-induced stimulation of cGMP was significantly inhibited by co-administration of
ODQ48 may indicate that cGMP may be involved with both ligands but by different mechanisms. Both ligands
appear capable of directly causing activation of sGC and cGMP accumulation but only H2 relaxin can activate the
RXFP1-p-ERK1/2-nNOS-NO-sGC-dependent pathway. H2 relaxin, B7-33 and ML290 have distinctly different
signalling profiles and will be useful tools to determine the relative importance of these profiles in the treatment
of cardiac failure and the anti-fibrotic effect. Further studies will be required to verify the contributions of the
mechanisms involved.
H2 relaxin has recently completed an extended phase III clinical trial for the treatment of AHF having previously been shown to improve dyspnoea and 180-day survival2. Although it has consistently been shown to be safe,
H2 relaxin has a number of disadvantages. The peptide displays cross-reactivity with other relaxin family peptide
receptors9, is not orally bioavailable and has a short half-life (<10 min)10. Thus, potent, selective small molecule
agonists of RXFP1 may have additional benefits, including oral bioavailability, a longer duration of action and a
more flexible treatment protocol. The biased signalling profile of ML290 with strong activation of cGMP signalling in vascular cells suggests that ML290 will display vasodilator and organ protective properties whereas the
lower potency for cAMP generation will minimise effects on VEGF expression and consequent angiogenesis. The
discovery of an allosteric biased small molecule agonist for RXFP1, with a half-life of several hours11, 13, could
have important implications for the treatment of AHF.
Relatively little has been published on other properties of ML290. However, it is known to have little or no
action at RXFP2, RXFP3 and AVPR1B, little cytotoxicity and to have high microsomal stability. The half-life in
plasma and heart is long (T1/2 8.56 and 7.48 h) and ML290 is concentrated in the heart13. While ML290 increased
VEGF expression in THP-1 cells it would be of interest to examine the longer-term effects in an in vivo model
on MMPs, tissue inhibitors of MMPs (TIMPs) and NOS to confirm potential anti-fibrotic properties. However,
given the species selectivity of ML290 development of an in vivo model will be challenging14. A better understanding of the effects of ML290 on NOS and ETB expression would also further enhance our knowledge of the
mechanisms underlying potential vasodilatory effects of ML290. Production and testing of mice with humanized
RXFP1 might resolve these questions. It is of paramount importance to determine if the findings seen in our study
can be translated to in vivo humanized mouse models .
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We have provided direct evidence that the first small molecule agonist at RXFP1, ML290, is an allosteric
biased agonist at RXFP1 that preferentially increases cGMP accumulation relative to cAMP in human vascular
cells and does not directly activate p-ERK1/2 in any of the systems studied. ML290 increased p-p38MAPK but
only in human primary smooth muscle cells and not in endothelial cells. Examination of the pattern of G protein
coupling in both recombinant and primary cell systems indicated that ML290 resembles relaxin in terms of the
conformational changes associated with Gαs coupling but is quite different with regard to GαOB coupling. The
signalling bias observed with ML290 towards cGMP and away from cAMP and particularly pERK1/2 suggests
vasodilator and antifibrotic actions while minimising effects on angiogenesis and hypertrophy.

Materials and Methods

Materials. Human gene 2 relaxin (H2 relaxin) was supplied by Corthera Inc. (San Mateo, CA, USA; a subsidiary of Novartis AG, Basel, Switzerland) and ML290 by National Center for Advancing Translational Sciences,
National Institutes of Health, Maryland, USA. NF023, NF449, mSIRK and L9A were purchased from Calbiochem
(Australia); gallein, pertussis toxin and forskolin from Sigma (Australia); foetal bovine serum (FBS) from JRH
Biosciences (KS, USA); coelenterazine h from Promega (WI, USA); geneJuice from Merck (Victoria, Australia);
and DEA NONOate from Cayman Chemicals (NSW, Australia).
Constructs.

G protein cDNA clones Gβ1 and Gα subunits Gαs, GαoB, Gαi3 were from Missouri S&T cDNA
Resource Cente (MO, USA) and Gγ2-Venus was kindly supplied by Prof Michel Bouvier (Université de Montréal,
Montréal, Quebec, Canada).

Cloning of RXFP1-Rluc8. A mammalian expression plasmid containing RXFP1-Rluc8 was produced by
modifying a pcDNA3.1 RXFP1-GFP2 plasmid (Svendsen et al., 2008). Briefly the GFP2 sequence was removed
from the plasmid utilizing engineered NotI and XhoI cut sites. The Rluc8 sequence was then amplified from
pcDNA V2R Rluc8 by RT-PCR using specific primers flanked by NotI and XhoI sites (Supplementary Table S1).
This PCR product was then cut with NotI and XhoI followed by ligation into the pcDNA3.1 RXFP1-GFP2 plasmid to create pcDNA3.1 RXFP1-Rluc8. The final plasmid insert was sequenced on both strands to ensure there
were no errors in the PCR amplification or cloning process.
Generation of cell lines stably expressing RXFP1.

A lentiviral construct containing RXFP1-Rluc8
under the control of the Ef1α promoter (pLenti6 Ef1α RXFP1-Rluc8) was generated using the multisite Gateway
cloning system (Invitrogen)49. Briefly, RXFP1-Rluc8 was generated using RT-PCR with primers containing
the required sequences at recombination sites in addition to 18–25 base pairs of template-specific sequence
from pcDNA3.1 RXFP1-rluc8 (Supplementary Table S1). The RXFP1-rluc8 PCR product was inserted into
the pDONR 221 P5-P2 backbone vector utilizing the BP ClonaseII enzyme (Invitrogen) to create the pENTR
L5-L2 RXFP1-Rluc8 entry vector. To generate the final pLenti6 Ef1α RXFP1-RlUC8, plasmid pENTR L5-L2
RXFP1-Rluc8 and pENTR L1-R5 Ef1α (kind gift of Dr Melanie White, Monash University) were added to the
destination vector pLenti6-Blockit-DEST and Clonase II Plus enzyme mix (Invitrogen). The final insert was
sequenced on both strands to ensure there were no errors in the PCR amplification or cloning process.
Lentiviruses were generated by co-transfection of 80% confluent HEK293T cells using Lipofectamine 2000
transfection reagent (Invitrogen, Life Technologies) with pLenti6 Ef1α RXFP1-Rluc8 and the packaging plasmids (pMDL, pRev and pVSVG; Kind gifts of Prof Alon Chen, Weizmann Institute of Science, Israel) which
provide the required trans-acting factors, namely Gag-Pol, Rev and the envelope protein VSVG, respectively50.
Lentivirus secreted into the media was collected and passed through a 30 mm diameter 0.45 μm Durapore PVDF
syringe filter (Millipore) to remove any cell particulates prior to storage at −80 °C. For the production of stable
cells expressing RXFP1-Rluc8, HEK293T cells seeded on a 10 cm cell culture dish were transduced with the harvested pLenti6 Ef1α RXFP1-Rluc8 recombinant lentivirus by replacing the cell culture media with 10 mL of the
virus-containing media, mixed with polybrene (Millipore) to increase the transduction efficiency. Two rounds of
24-hour transduction were performed before the cells were allowed to recover for 48 hours in complete DMEM.
The cells were then transferred to 175 cm2 flasks and grown to confluency. Transduced cells were FACS sorted
(Becton Dickinson FACS AriaIII) utilizing an anti-FLAG antibody to detect the N-terminal FLAG tag on the
receptor as previously described and the highest cell surface receptor expressing cells collected51. Only the top
10% of cells with fluorescence levels significantly higher than the background fluorescence in non-transfected
HEK293T control cells were collected. Sorted cells were propagated in complete DMEM for use in assays.

Cell Culture. HEK293 parental cells and cells stably expressing RXFP1 (HEK-RXFP1) were cultured in
DMEM containing 5% (v/v) FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and maintained at 37 °C under
5% CO2. Transient transfections of HEK-RXFP1 cells were carried out 24 h after seeding using GeneJuice (Merck,
Kilsyth, Australia) according to the manufacturer’s instructions. Primary cultures of human umbilical artery
endothelial cells (HUAEC), human umbilical vein endothelial cells (HUVEC), human coronary artery endothelial cells (HCAEC), human umbilical artery smooth muscle cells (HUASMC) and human umbilical vein smooth
muscle cells (HUVSMC) were obtained from ScienCell Research Laboratories (San Diego, U.S.A) and cultured
as detailed previously6. Human foetal cardiac fibroblasts (HCF) were characterized by the presence of fibronectin (ScienCell). Cells were maintained in Medium 199 containing 5% FBS, 100 units/ml penicillin, 100 µg/ml
streptomycin and the relevant growth supplements for optimal growth of each cell type (ScienCell) and maintained at 37 °C under 5% CO2. Fibroblasts were grown in fibroblast cell growth supplement-2 (BSA 10 μg/ml,
apo-transferrin 10 μg/ml, insulin 7.5 μg/ml, EGF 2 ng/ml, FGF-2 2 ng/ml, hydrocortisone 1 μg/ml) (information
provided by ScienCell). Early passage primary cell cultures (2–5) were used for all experiments.
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Radioligand binding.

Competition radioligand binding studies were performed in HEK-RXFP1 cells as
described previously23. Briefly, HEK-RXFP1 cells were incubated with 100pM of 125I-H2 relaxin and allowed
to compete with increasing concentrations of unlabelled H2 relaxin in the presence of ML290 or vehicle (0.1%
DMSO). After 90 min incubation at room temperature, the reaction was terminated with the removal of medium
and washing with cold PBS. Cells were digested with 0.1 M NaOH and radioactivity counted on the γ-counter.

Kinetic studies. Association and dissociation kinetic studies were performed using 125I-H2 relaxin. Briefly,
HEK-RXFP1 cells were plated in 96-well plates and allowed to adhere overnight. After rinsing with PBS, the cells
were incubated at the given time intervals with 100pM of 125I-H2 relaxin to measure the association rate. The dissociation rate of ML290 was calculated using ligand competition. Cells were allowed to equilibrate with 100 pM of
125
I-H2 relaxin for 90 mins prior to the addition of unlabelled 200 nM H2 relaxin for the given time intervals. The
reactions were terminated by the removal of medium and washing with ice-cold PBS. Cells were digested using
0.1 M NaOH and radioactivity counted on the γ-counter.
ERK1/2, p38MAPK or JNK1/2 Phosphorylation Assays. p-ERK1/2, p-p38MAPK and p-JNK1/2 was
measured using the Surefire ERK, p38 and JNK kits (TGR BioSciences, Australia) as described previously6, 16.
Briefly, HEK-RXFP1 cells were plated into 96-well plates (5 × 104 cells/well) and primary cells grown in 24-well
plates (1 × 105 cells/well) overnight to achieve a confluent monolayer. Prior to stimulation, HEK293 cells were
serum-starved with DMEM containing 0.5% (v/v) FBS and primary cells in M199 medium for 4–6 hours. The
effect of ML290 on H2 relaxin-stimulated p-ERK1/2 was examined by addition of ML290 (10−5 M or 10−6 M) or
vehicle (DMSO) to HEK-RXFP1 cells for 10 min at 37 °C followed by H2 relaxin (10−5 M–10−12 M) and incubation at 37 °C for 4 min (maximal response). Levels of p-ERK1/2, p-p38MAPK and p-JNK1/2/3 were detected as
per manufacturer’s instructions (Perkin-Elmer, Australia).
cAMP and cGMP Accumulation Assays. cAMP and cGMP accumulation was determined as previously

described6, 16. Briefly, HEK293 cells were plated in 96-well plates (5 × 104 cells/well) and human primary cells were
plated into 24-well plates (1 × 105 cells/well) and grown overnight to achieve a confluent monolayer. Prior to stimulation, HEK cells were serum-starved in DMEM containing 0.5% FBS v/v and primary cells were serum-starved
in M199 medium for 4–6 hours. Where appropriate, cells were pre-incubated with mSIRK (5 μM, 30 min), mSIRK
control peptide L9A (5 μM, 30 min), gallein (100 μM, 30 min), Wortmannin (100 nM, 30 min), NF023 (10 μM,
30 min) and NF449 (10 μM, 30 min). Levels of cAMP and cGMP were detected according to the manufacturer’s
instructions (Perkin-Elmer, Australia).

Gelatin zymography.

Changes in matrix metalloproteinases-2 (MMP-2; gelatinase A) activity that were
secreted from HCFs into the cell media over a 72 hour experimental period, were assessed by gelatin zymography
as described previously44, 45. Cells were treated with either ML290 (1 μM), H2 relaxin (0.1 μM; a 10-fold lower
concentration based on the cGMP concentration-response curve) or vehicle (0.1% DMSO) for 72 hours and analysed for MMP-2 expression. Cells were used between passages 1–4, while all experiments were performed four
separate times in duplicate. The optical density (OD) of MMP-2 was measured using a GS710 Calibrated Imaging
Densitomer (Bio-Rad Laboratories, Hercules, CA, USA), and the mean ± SE OD of MMP-2 in each treated group
was expressed as the relative ratio of the values in the untreated control group.

Smad2 and Smad3 Phosphorylation Assays. To evaluate the anti-fibrotic effect of ML290 and compare

it to H2 relaxin in HCFs were plated into 24-well plates (0.7 × 105 cells/well) and grown overnight to achieve a
confluent monolayer. Cells were treated with either ML290 (1 μM), H2 relaxin (0.1 μM) or vehicle (0.1% DMSO)
or in combination with TGF-β1 (2 ng/ml final concentration) for 72 hours. Cells were serum-starved in M199
medium for 24 hours prior sample collection. Cells were used between passages 1–4, while all experiments were
performed four separate times in duplicate. Levels of p-Smad2 and p-Smad3 were detected using Sure-fire kits
according to the manufacturer’s instructions (Perkin-Elmer, Australia).

Real-time kinetic BRET assays. HEK293 cell were seeded in 6-well plates at a density of 600,000 cells
per well and transfected with constructs encoding the tagged receptors and signalling proteins. 24 h later cells
were harvested in HEPES-buffered phenol red-free medium containing 5% FBS and plated out in a white 96-well
plate (Nunc) that was incubated at 37 °C under 5% CO2. BRET assays were performed 48 h after transfection
as described previously16, 52. Medium was replaced with phenol-red-free-DMEM supplemented with 5% FBS
plus 5 μM coelenterazine h. BRET measurements were made at 37 °C using the PHERAstar Omega plate reader
with Omega software (BMG LABTECH, Germany). Filtered light emissions were simultaneously measured in
each of the “donor wavelength window” (475 ± 15 nm for Rluc8 with coelenterazine h) and “acceptor wavelength window” (535 ± 15 nm for Venus). Cells were assayed before and after treatment with ligands or 5% FBS
phenol-red-free-DMEM medium containing 0.01% w/v BSA (vehicle). The BRET signal was calculated as previously described52.
Data Analysis.

Data was analysed using GraphPad Prism v6.0. All data represents the mean ± S.E.M of ‘n’
individual experiments performed in duplicate. Concentration-response curves were fitted either using a sigmoidal or Gaussian model. Kinetic data was plotted using the association and dissociation models to calculate kon
and koff. Statistical significance was determined using a Student’s t-test or a one-way ANOVA with a Dunnett’s
post-hoc test with significance accepted at p < 0.05.
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